Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 1
2017 3
2018 3
2019 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Tavaborole in Difficult-to-Treat Onychomycosis Cases: A Post-hoc Assessment of Phase III Subjects.
Aly R, Gupta AK, Winter T, Zane LT, Vlahovic T. Aly R, et al. J Drugs Dermatol. 2017 Oct 1;16(10):1016-1021. J Drugs Dermatol. 2017. PMID: 29036255 Clinical Trial.
We present a case series of 4 patients, of varying age and difficult-to-treat clinical features, which responded positively to tavaborole 5% solution. Three of the subjects achieved complete cure after being treated with tavaborole 5%, with one additional subject (a …
We present a case series of 4 patients, of varying age and difficult-to-treat clinical features, which responded positively to tavaborole
Tavaborole 5% Topical Solution for the Treatment of Toenail Onychomycosis in Pediatric Patients: Results from a Phase 4 Open-Label Study.
Rich P, Spellman M, Purohit V, Zang C, Crook TJ. Rich P, et al. J Drugs Dermatol. 2019 Feb 1;18(2):190-195. J Drugs Dermatol. 2019. PMID: 30811142 Clinical Trial.
Background: This study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of tavaborole in pediatric patients. Study Design: In this open-label, single-arm study, pediatric patients (aged 6 to <17 years) with distal subungual onychomy …
Background: This study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of tavaborole in pediat …
Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies.
Elewski BE, Aly R, Baldwin SL, González Soto RF, Rich P, Weisfeld M, Wiltz H, Zane LT, Pollak R. Elewski BE, et al. J Am Acad Dermatol. 2015 Jul;73(1):62-9. doi: 10.1016/j.jaad.2015.04.010. Epub 2015 May 5. J Am Acad Dermatol. 2015. PMID: 25956661 Free article. Clinical Trial.
OBJECTIVE: We sought to evaluate the efficacy and safety of tavaborole topical solution, 5% for treatment of toenail onychomycosis. ...Rates of completely or almost clear nail plus negative mycology (15.3%-17.9% vs 1.5%-3.9%) were significantly greater for tavaborole
OBJECTIVE: We sought to evaluate the efficacy and safety of tavaborole topical solution, 5% for treatment of toenail onychomycosis. . …
The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis.
Toledo-Bahena ME, Bucko A, Ocampo-Candiani J, Herz-Ruelas ME, Jones TM, Jarratt MT, Pollak RA, Zane LT. Toledo-Bahena ME, et al. J Drugs Dermatol. 2014 Sep;13(9):1124-32. J Drugs Dermatol. 2014. PMID: 25226015 Clinical Trial.
In cohort 3 of study 2, 7% of patients achieved treatment success with tavaborole 5.0% at day 360. Negative culture rates at day 180 in study 1 were numerically higher for tavaborole 2.5%, 5.0%, and 7.5% vs vehicle (slope P=0.046). ...Based on these findings, tav
In cohort 3 of study 2, 7% of patients achieved treatment success with tavaborole 5.0% at day 360. Negative culture rates at day 180 …
Long-Term Follow-up of Onychomycosis Patients Treated With Efinaconazole.
Pollak RA, Ilie C. Pollak RA, et al. J Drugs Dermatol. 2017 Dec 1;16(12):1269-1273. J Drugs Dermatol. 2017. PMID: 29240863 Clinical Trial.
BACKGROUND: Onychomycosis is a common disease that remains difficult to treat despite the introduction of new topical agents. Clinical trials on efinaconazole and tavaborole included 48 weeks' daily treatment regimens with a 4-week follow-up. ...
BACKGROUND: Onychomycosis is a common disease that remains difficult to treat despite the introduction of new topical agents. Clinical trial …
Topical Tavaborole in the Treatment of Onychomycosis Complicated by Dermatophytoma: A Post-hoc Assessment of Phase II Subjects.
Aly R, Winter T, Hall S, Vlahovic T. Aly R, et al. J Drugs Dermatol. 2018 Mar 1;17(3):347-354. J Drugs Dermatol. 2018. PMID: 29537453 Clinical Trial.
In this respect, dermatophytoma is generally treated with a combination therapy approach, often including both surgical and pharmacologic intervention for improved outcomes. A post-hoc assessment of Phase II tavaborole onychomycosis studies was conducted in order to assess …
In this respect, dermatophytoma is generally treated with a combination therapy approach, often including both surgical and pharmacologic in …
Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies.
Gupta AK, Hall S, Zane LT, Lipner SR, Rich P. Gupta AK, et al. J Dermatolog Treat. 2018 Feb;29(1):44-48. doi: 10.1080/09546634.2017.1329510. Epub 2017 May 30. J Dermatolog Treat. 2018. PMID: 28521541 Clinical Trial.
The current study evaluated durability of clinical benefit of tavaborole topical solution, 5%, for the treatment of toenail onychomycosis. ...RESULTS: Of the 62 patients who completed the PSFU, complete cure was higher in the tavaborole-treated group versus the vehi …
The current study evaluated durability of clinical benefit of tavaborole topical solution, 5%, for the treatment of toenail onychomyc …
Planimetric Post-hoc Analysis of Women With Onychomycosis from Tavaborole 5% Phase III Studies: Evidence of Greater Improvements in Patients With >50% Baseline Infection.
Pariser DM, Wendelken ME, Rycerz AM Jr, Gellings Lowe N, Yost JM, Lipner SR. Pariser DM, et al. J Drugs Dermatol. 2018 Feb 1;17(2):168-172. J Drugs Dermatol. 2018. PMID: 29462224 Clinical Trial.
There is limited female-specific data on the treatment of onychomycosis. Tavaborole is a topical treatment option for onychomycosis. This post-hoc study evaluated the nail plates of women using data from the tavaborole 5% Phase III studies at baseline and end of stu …
There is limited female-specific data on the treatment of onychomycosis. Tavaborole is a topical treatment option for onychomycosis. …
Labeled use of efinaconazole topical solution 10% in treating onychomycosis in children and a review of the management of pediatric onychomycosis.
Gupta AK, Venkataraman M, Shear NH, Piguet V. Gupta AK, et al. Dermatol Ther. 2020 Jul;33(4):e13613. doi: 10.1111/dth.13613. Epub 2020 Jul 18. Dermatol Ther. 2020. PMID: 32418289 Clinical Trial.
Efinaconazole topical solution 10% is effective and safe in treating onychomycosis in children age 6 to 16 years and was recently FDA-approved for this indication. The on-label use of other topical agents, tavaborole solution 5% and ciclopirox nail lacquer solution 8% is r …
Efinaconazole topical solution 10% is effective and safe in treating onychomycosis in children age 6 to 16 years and was recently FDA-approv …